Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2010-03-01 Investor Presentation
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Investor Presentation 36 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a detailed investor presentation from March 2010 by Pharmaxis, focusing on therapeutic products for respiratory diseases, specifically highlighting clinical trial phases, product pipelines, and detailed clinical trial results for Bronchitol in cystic fibrosis. It contains forward-looking statements, company overview, clinical trial data, treatment progression, and market research insights. There is no indication that this is a regulatory filing, audit report, earnings release, or annual/interim report. The content is consistent with an investor presentation aimed at providing detailed financial, clinical, and strategic information to investors. The length (15,000 characters) and detailed content support this classification rather than a brief announcement or report publication notice.
2010-03-01 English
Pharmaxis completes clinical trial with PXS25 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release dated 09 February 2010 from Pharmaxis Ltd announcing the completion of a Phase I clinical trial for their drug candidate PXS25. It provides details about the trial design, results, and future plans. The content is a corporate announcement about clinical trial progress rather than a financial report, regulatory filing, or management discussion. It does not contain financial statements, voting results, or governance information. It is not a report publication announcement since it is a standalone announcement of clinical trial completion. Therefore, the document best fits the category of a general regulatory announcement or corporate update that does not fit other specific categories, which corresponds to Regulatory Filings (RNS).
2010-02-08 English
Pharmaxis completes acquisition of Topigen Pharmaceuticals 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a media release dated 9 February 2010 announcing the completion of an acquisition by Pharmaxis Ltd of the Canadian company TOPIGEN Pharmaceuticals Inc. It details the issuance of shares related to the acquisition and provides background information on both companies and the drug candidates involved. There are no financial statements, regulatory certifications, or detailed financial performance data included. The document is a corporate announcement about a financing and acquisition event rather than a full report or regulatory filing. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share issuance related to acquisitions.
2010-02-08 English
Appendix 3B - Topigen Acquisition 10 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX (Australian Securities Exchange) rules and regulations. It details the issuance of fully paid ordinary shares, the number of securities issued, issue price, purpose of the issue, and other related information about the new securities. The document is a formal announcement of a new share issue and application for quotation of additional securities on the ASX. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is a regulatory announcement specifically about a capital raising event and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the securities issued, supporting a high confidence in classification.
2010-02-08 English
Disclosure notice under section 708A(5) of Corporations Act 1
Capital/Financing Update Classification · 95% confidence The document is a disclosure notice under section 708A(5)(e) of the Corporations Act 2001 (Cth), relating to the issuance and allotment of ordinary shares without disclosure under Part 6D.2 of the Corporations Act. It mentions compliance with relevant provisions and confirms no excluded information. The document is short (1487 characters) and is a formal regulatory disclosure about share issuance, not a full financial report or announcement of financial results. This fits the category of Capital/Financing Update (CAP), as it concerns company fundraising and capital structure changes through share issuance.
2010-02-08 English
Half Yearly Report and Accounts 19 pages ?Kb
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ASX Half year report – 31 December 2009' and references the half-year ended 31 December 2009, indicating it is an interim financial report. It includes detailed financial statements such as consolidated income statement, balance sheet, cash flows, notes, directors' report, and auditor's review report. The content includes substantive financial data and analysis for the half-year period, not just an announcement or summary. The document is about 15,000 characters long, which is consistent with a full interim report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2010
2010-02-04 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.